Skip to main content
Rohit Aggarwal, MD, Rheumatology, Pittsburgh, PA, UPMC Presbyterian Shadyside

RohitAggarwalMD

Rheumatology Pittsburgh, PA

Assistant Professor, Medicine, University of Pittsburgh School of Medicine

Dr. Aggarwal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Aggarwal's full profile

Already have an account?

Education & Training

  • Rush University Medical Center
    Rush University Medical CenterFellowship, Rheumatology, 2007 - 2009
  • UPMC Medical Education
    UPMC Medical EducationResidency, Internal Medicine, 2004 - 2007
  • Delhi University College of Medical Sciences
    Delhi University College of Medical SciencesClass of 2003

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2023 - Present
  • ME State Medical License
    ME State Medical License Current
  • PA State Medical License
    PA State Medical License 2004 - 2024
  • IL State Medical License
    IL State Medical License 2007 - 2011
  • American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
  • Fellow American College of Rheumatology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Author Correction: Treatment in Myositis  
    Chester V Oddis, Rohit Aggarwal, Nature

Lectures

  • Autoantibodies Predict Treatment Response to Rituximab in Myositis 
    76th Annual Scienific Meeting, Washington, DC, USA
  • Autoantibodies Predict Treatment Response to Rituximab in Myositis 
    American College of Rheumatology, 76th Annual Scienific Meeting, Washington, DC, USA

Other

Press Mentions

  • CT Results in Myositis Inform Cancer Screening Strategies
    CT Results in Myositis Inform Cancer Screening StrategiesMarch 24th, 2023
  • FDA Approves IV Immunoglobulin to Treat Adults with Dermatomyositis
    FDA Approves IV Immunoglobulin to Treat Adults with DermatomyositisAugust 17th, 2021
  • FDA Approves Octapharma’s Octagam® 10% for Adult Dermatomyositis
    FDA Approves Octapharma’s Octagam® 10% for Adult DermatomyositisJuly 20th, 2021
  • Join now to see all

Hospital Affiliations